KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Gilead Sciences (GILD) over the last 17 years, with Q3 2025 value amounting to $71.0 million.

  • Gilead Sciences' Gains from Investment Securities rose 68888.89% to $71.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$174.0 million, marking a year-over-year decrease of 92352.94%. This contributed to the annual value of $492.0 million for FY2024, which is 15956.42% up from last year.
  • As of Q3 2025, Gilead Sciences' Gains from Investment Securities stood at $71.0 million, which was up 68888.89% from $142.0 million recorded in Q2 2025.
  • Gilead Sciences' 5-year Gains from Investment Securities high stood at $410.0 million for Q1 2024, and its period low was -$470.0 million during Q4 2023.
  • Its 5-year average for Gains from Investment Securities is -$83.6 million, with a median of -$142.0 million in 2021.
  • Per our database at Business Quant, Gilead Sciences' Gains from Investment Securities plummeted by 42280.7% in 2022 and then soared by 68888.89% in 2025.
  • Quarter analysis of 5 years shows Gilead Sciences' Gains from Investment Securities stood at $57.0 million in 2021, then tumbled by 422.81% to -$184.0 million in 2022, then crashed by 155.43% to -$470.0 million in 2023, then surged by 108.3% to $39.0 million in 2024, then soared by 82.05% to $71.0 million in 2025.
  • Its Gains from Investment Securities was $71.0 million in Q3 2025, compared to $142.0 million in Q2 2025 and -$426.0 million in Q1 2025.